SCHEMBL7142813

SCHEMBL7142813

O=S(=O)(c1ccccc1)N(CCc1ccccc1)C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.56
OPRM1 P35372 2/20 0.55
CHRM2 P08172 4/20 0.50
CHRM3 P20309 4/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
DRD2 P14416 2/20 0.47
HTR2C P28335 2/20 0.47
KCNH2 Q12809 1/20 0.47
CXCR4 P61073 2/20 0.46
HTR2B P41595 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
ACHE P22303 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7141075 0.93 HTT (0.56) HTR2AOPRM1CHRM2CHRM3SIGMAR1
SCHEMBL7141347 0.93 CHRM4 (0.52) HTR2AOPRM1CHRM2CHRM3MEN1
SCHEMBL7141098 0.92 OPRM1 (0.53) HTR2AOPRM1CHRM2CHRM3MEN1
SCHEMBL14045066 0.82 HTR6 (0.48) HTR2AOPRM1CHRM2CHRM3MEN1
SCHEMBL14997384 0.81 HTR2A (0.61) HTR2AOPRM1CHRM2CHRM3DRD2
SCHEMBL1682296 0.81 HTR2A (0.53) HTR2AOPRM1CHRM2CHRM3DRD2
SCHEMBL7147151 0.79 HTR2A (0.58) HTR2AOPRM1CHRM2CHRM3MEN1
SCHEMBL7148857 0.78 MEN1 (0.56) OPRM1CHRM2CHRM3MEN1KMT2A
SCHEMBL7142628 0.78 KMT2A (0.62) HTR2AOPRM1CHRM2CHRM3MEN1
SCHEMBL13681390 0.77 PSEN1 (0.43) MEN1KMT2APSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US claimed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP claimed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO claimed
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US disclosed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP disclosed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176461-A1 Aminopiperidines SLC1A2, SLC6A4, SLC1A1 HTR2A 45/4885OPRM1 242/4885CHRM2 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.